Clinical and Molecular Investigations Into Ciliopathies |
Maryland |
6 months - 80 years |
No longer recruiting |
Active |
Info
|
PKD Clinical and Translational Core Study (PKD Core) |
Maryland |
18 and older |
Recruiting |
Active |
Info
|
Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q) |
Minnesota |
18 and older |
Recruiting |
Active |
Info
|
Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping (ADPKD) |
New York |
18 and older |
Recruiting |
Active |
Info
|
Polycystic Kidney Disease Data Repository |
New York |
18 and older |
Recruiting |
Active |
Info
|
Transplant Registry: Patients Who May Require Transplantation and Those Who Have Undergone Transplantation of Liver, Kidney and/or Pancreas |
Virginia |
Child, adult, senior |
Recruiting |
Active |
Info
|
Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD (GeneQuest) |
France |
16 and older |
Recruiting |
Active |
Info
|
Lanreotide in Polycystic Kidney Disease Study (LIPS) |
France |
18 and older |
No longer recruiting |
Active |
Info
|
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease (TAME) |
Maryland and Massachusetts |
18-60 |
No longer recruiting |
Active |
Info
|
PKD Biomarkers Repository Study |
Kansas City - Missouri and Kansas |
Birth to age 35 |
Recruiting |
Active |
Info
|
A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe |
Multiple Locations
|
18 and older |
Not recruiting |
Active |
Info
|
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD |
Colorado |
6-25 |
Recruiting |
Active |
Info
|
Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Patients (Autosomal Dominant Polycystic Kidney Disease) |
France |
18 and older |
Recruiting |
Active |
Info
|
Canadian Medical Assessment of JINARC™ Outcomes Registry |
Canada |
18 and older |
Recruiting |
Active |
Info
|
Efficacy of Tolvaptan on ADPKD Patients |
Japan |
18 and older |
Not recruiting |
Active |
Info
|
Feasibility Study of Metformin Therapy in ADPKD |
Colorado |
30-60 |
Recruiting |
Active |
Info
|
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD |
Japan |
Child, adult, senior |
Recruiting |
Active |
Info
|
Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD |
Multiple Locations
|
4-17 |
Recruiting |
Active |
Info
|
The German ADPKD Tolvaptan Treatment Registry |
Germany |
18 and older |
Recruiting |
Active |
Info
|
ARPKD and ARPKD-Related Diseases Database |
North
Central and South America |
up to 35 |
Recruiting |
Active |
Info
|
Using Preimplantation Genetic Diagnosis in Autosomal Dominant Polycystic Kidney Disease Patients: a Multicenter Clinical Trial |
China |
20-35 |
Recruiting |
Active |
Info
|
A Randomised Feasibility Trial of High Water Intake in Polycystic Kidney Disease |
United Kingdom |
16 and older |
Not yet recruiting |
Active |
Info
|
An international multicenter registry study on autosomal recessive polycystic kidney disease (ARPKD) - ARegPKD |
Multiple locations |
Any age |
Recruiting |
Active |
Info
|
A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD) |
Pennsylvania
Wisconsin |
5-12 |
Not recruiting |
Active |
Info
|
Tesevatinib in Subjects With ADPKD |
Multiple Locations
|
18-60 |
Recruiting |
Active |
Info
|
A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease |
New York |
18-65 |
Recruiting |
Active |
Info
|
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases |
Multiple Locations
|
18-65 |
Recruiting |
Active |
Info
|
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease |
Colorado |
18-65 |
Recruiting |
Active |
Info
|
Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2) |
Kansas |
18-60 |
Not recruiting |
Active |
Info
|
Assessment of longitudinal changes in endothelial function and oxidative stress in normotensive patients with ADPKD |
Minnesota |
18-40 |
Recruiting |
Active |
Info
|
Genetics of Brain Aneurysm Formation in Autosomal Dominant Polycystic Kidney Disease |
Maryland
Connecticut |
18 and older |
Recruiting |
Active |
Info
|
ELiSA, a Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Lixivaptan in Subjects with Autosomal Dominant Polycystic Disease |
Multiple Locations
|
18-65 |
Recruiting |
Active |
Info
|
Dynamic Measurement of Renal Functional Reserve as a Predictor of Long-Term Renal Function |
Switzerland |
18 and older |
Recruiting |
Active |
Info
|
Samsca PMS in ADPKD Patients |
Korea |
18 and older |
Recruiting |
Active |
Info
|
Statin Therapy in Patients with Early Stage ADPKD |
Colorado |
25-60 |
Recruiting |
Active |
Info
|
Tolvaptan-Octreotide LAR Combination in ADPKD |
Italy |
18 and older |
Not yet recruiting |
Active |
Info
|
Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease (RAP) |
Austria |
18 and Older |
Recruiting |
Active |
Info
|
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients (STAGED-PKD) |
Texas |
18 to 50 |
Recruiting |
Active |
Info
|
ADPKD Alterations in Hepatic Transporter Function |
North Carolina |
18 to 65 |
Recruiting |
Active |
Info
|